摘要
目的探讨麝香保心丸联合依折麦布治疗老年冠心病患者的疗效,以期为临床治疗提供参考。方法选取2020年1月—2022年2月在河南省南阳市第一人民医院治疗的120例冠心病患者为研究对象。采用随机数字表法,将患者分为观察组与对照组,每组60例。对照组患者采用依折麦布治疗,观察组患者在对照组基础上加用麝香保心丸治疗。比较2组患者治疗效果。比较2组患者治疗前后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平及左室射血分数(LVEF)、左室短轴缩短率(LVFS)、血小板聚集率。比较2组患者治疗后健康调查简表(SF-36)评分。结果观察组患者治疗总有效率为98.33%,高于对照组的83.33%,差异有统计学意义(P<0.05)。治疗前,2组患者LVEF、LVFS及血小板聚集率比较,差异无统计学意义(P>0.05)。治疗后,2组患者LVEF、LVFS高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组患者血小板聚集率低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗前,2组患者TG、TC、LDL-C及HDL-C水平比较,差异无统计学意义(P>0.05)。治疗后,2组患者TG、TC、LDL-C水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组患者HDL-C水平均高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组患者SF-36中认知功能、角色功能、情绪功能、躯体功能、社会功能评分均高于对照组,差异均有统计学意义(P<0.05)。结论麝香保心丸联合依折麦布治疗老年冠心病能改善患者的心功能,提高治疗效果,还能降低患者的血小板聚集率,改善患者的血脂状况,进而提高患者的总体生活质量。
Objective This study aimed to investigate the efficacy of Shexiang Baoxin Pills combined with Ezetimibe in the treatment of elderly patients with coronary heart disease,in order to provide support for clinical treatment.Methods A total of 120 patients with coronary heart disease who were treated in the First People's Hospital of Nanyang from January 2020 to February 2022 were selected as the study participants.They were assigned to the observation group and control group by random number table,with 60 cases in each group.The patients in the control group received Ezetimibe,and the patients in the observation group received Shexiang Baoxin Pills on the basis of the control group.The therapeutic effect was compared between the 2 groups.The levels of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS)and the platelet aggregation.were compared between the two groups before and after treatment.The 36-Item Short-Form Health Survey scores were compared between the 2 groups.Results The overall response rate in the observation group was significantly higher than that of the control group(98.33%vs.83.33%,P<0.05).Before treatment,there was no significant difference in LVEF,LVFS,and platelet aggregation rate between the two groups(P>0.05).After treatment,LVEF and LVFS in the two groups were higher than those before treatment,and the observation group was higher than the control group,and the differences were statistically significant(P<0.05).After treatment,the platelet aggregation rate in the two groups was decreased,and the observation group was lower than the control group,and the differences had statistical significance(P<0.05).Before treatment,there was no significant difference in TG,TC,LDL-C,and HDL-C levels between the two groups(P>0.05).After treatment,TG,TC,and LDL-C levels in the two groups were lower than those before treatment,and the observation group was lower than the control group,with statistical significance(P<0.05).After treatment,HDL-C levels in both groups were higher than those before treatment,and the observation group was higher than the control group,with statistical significance(P<0.05).After treatment,the scores of mental health,role physical,role emotional,physical functioning,and social functioning in the SF-36 in the observation group were higher than those in the control group,with statistical significance(P<0.05).Conclusion Shexiang Baoxin Pills combined with Ezetimibe in the treatment of elderly patients with coronary heart disease can potentiate cardiac function,improve the therapeutic effect,reduce the platelet aggregation rate,enhance the blood lipid status and raise the overall quality of life of patients.
作者
孙富强
Sun Fuqiang(Department of Cardiovascular Medicine,the First People's Hospital of Nanyang,Nanyang Henan 473000,China)
出处
《保健医学研究与实践》
2023年第2期12-15,共4页
Health Medicine Research and Practice
关键词
麝香保心丸
依折麦布
老年人
冠心病
Shexiang Baoxin pills
Ezetimibe
Elderly
Coronary heart disease
